CCRC Closes ￥10M Series A Financing

(VCBeat) Feb. 23, 2021 -- Cardiovascular Chinese Research Center ("CCRC") recently it has closed its Series A financing worth tens of millions of yuan, led by Huaige Capital, with participation from Shanghai Bestudy and Shanghai Nabotong.  The funding will be used to build the characteristic SMO business layout and the core laboratory of CCRC.

CCRC is a medical device CRO company providing the whole-process and differentiated service platform, characteristic SMO business, and Core-Lab. It is deeply engaged in interventional medical devices, with extensive network resources of experts, rich experience in interventional medical device CRO, good management system and project execution.

Prior to this financing, there was a restructuring of assets of CCRC, which enables  CCRC to provide medical device CRO services of the whole industry chain for the whole life cycle of medical devices. Guo Gongjian, Chairman of CCRC, said, "CCRC will provide manufacturing quality system construction, animal experiment services, medical writing, planning and implementation of clinical trials, data management and statistical analysis, core imaging laboratory and other services for companies. Our project management is compliant with ISO9001 and ISO13485, and we have helped many partners to obtain their certificates of product registration ." 

Founded in 2016 by Mr. Kai Wang. Huaige Capital is a Shanghai-headquartered venture capital focusing on the healthcare sector (medical devices, innovative drugs, biologics, outsourcing services, etc.), and preferably invest at early or growth stage. They foster "active investment" as well as "in-depth value-added services" as their principal strategy, and aim to be a boutique venture capital within the healthcare sector. In line with the spirit of "integration and specialization", the company is committed to creating greater value for both its investors and its portfolio companies.

Founded in 2010, Bestudy is an international company focusing on the clinical development of new drugs. The company has cooperated with more than 300 hospitals in China. It provides clinical research services in the fields of pharmaceuticals, medical devices and biological products.